Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/2/2025

Treatment of Dermatophyte Infections

Introduction to Dermatophyte Infections

  • The British Journal of Dermatology recommends terbinafine as the first-line treatment for dermatophyte onychomycosis and other dermatophyte infections due to its superior fungicidal activity, higher cure rates, and lower relapse rates compared to azole antifungals 1, 2

Superior In Vitro and In Vivo Activity

  • Terbinafine demonstrates true fungicidal activity against dermatophytes, with a minimum inhibitory concentration (MIC) of approximately 0.004 µg/mL that equals its minimal fungicidal concentration (MFC), making it the most active antidermatophyte agent available 3, 4
  • Itraconazole has 10-fold higher MIC and MFC values than terbinafine, indicating significantly weaker antifungal potency against dermatophytes 3, 4
  • Terbinafine has particularly potent fungicidal effects against Trichophyton rubrum and T. mentagrophytes, the most common causative organisms in dermatophyte infections 2

Clinical Efficacy

  • Complete cure rates in dermatophyte toenail onychomycosis were 55% with terbinafine versus 26% with pulsed itraconazole in a large multicenter randomized trial of 508 patients 1
  • At 5-year follow-up, terbinafine maintained superior outcomes, with mycological cure without retreatment being 46% versus 13% for itraconazole 1
  • Relapse rates were significantly lower with terbinafine, with mycological relapse occurring in 23% versus 53% with itraconazole, and clinical relapse in 21% versus 48% 1

Mechanism of Action Advantage

  • Terbinafine inhibits squalene epoxidase, blocking ergosterol biosynthesis and causing toxic accumulation of intracellular squalene, resulting in both fungistatic and fungicidal effects 2, 5
  • Azoles are primarily fungistatic rather than fungicidal, which contributes to their lower cure rates and higher relapse rates in dermatophyte infections 3

Practical Treatment Considerations

  • Terbinafine requires shorter treatment duration: 250 mg daily for 6 weeks (fingernails) or 12-16 weeks (toenails) 1, 2
  • Itraconazole requires either 12 weeks continuous therapy or pulse therapy, which may be less convenient 1, 2
  • Terbinafine has minimal drug-drug interactions, with only potentially significant interaction involving cytochrome P450 2D6 substrates 2
  • Itraconazole has extensive drug interactions, including enhanced toxicity with warfarin, antihistamines, antipsychotics, anxiolytics, digoxin, cisapride, ciclosporin, and simvastatin 4

Safety Profile

  • Common terbinafine side effects are mild: gastrointestinal disturbances and dermatological events such as rash or pruritus, with serious adverse events occurring in only 0.04% of patients 2
  • Important caveat: Taste disturbance occurs in approximately 1:400 patients and can rarely be permanent—patients must be warned of this risk 2
  • Both agents are contraindicated in active or chronic liver disease and require baseline liver function monitoring in high-risk patients 2, 5

When Azoles May Be Preferred

  • For Candida onychomycosis, itraconazole is superior as terbinafine has only fungistatic activity against Candida species while azoles demonstrate better anti-Candida efficacy 6, 2
  • When terbinafine is contraindicated, itraconazole becomes the next best alternative 4, 5

Terbinafine vs Fluconazole: Side Effect Profile Comparison

Direct Comparative Evidence

  • Fluconazole has a significantly higher rate of adverse events leading to treatment discontinuation compared to terbinafine, with 20-58% of patients discontinuing fluconazole versus approximately 10.5% experiencing any adverse events with terbinafine, according to the British Journal of Dermatology 7

Common Side Effects by Agent

  • Terbinafine had a superior tolerability profile with adverse events occurring in only 10.5% of patients, with gastrointestinal complaints being most common, as reported by the British Journal of Dermatology 8
  • Fluconazole showed adverse effects leading to treatment discontinuation in 20% of patients receiving 150 mg weekly, escalating dramatically to 58% at higher weekly doses, according to the British Journal of Dermatology 7
  • The British Journal of Dermatology notes that fluconazole's use has been "relatively limited because of side-effects" 9

Hepatotoxicity Risk Comparison

  • Terbinafine requires baseline liver function tests in patients with a history of hepatotoxicity, and active or chronic liver disease is a contraindication, as recommended by the British Journal of Dermatology 10
  • Fluconazole requires baseline liver function tests and monitoring in high-dose or prolonged therapy, according to the British Journal of Dermatology 10

Practical Clinical Implications

  • For patients on multiple medications, terbinafine is the safer choice due to its minimal drug interaction profile, and for patients requiring higher doses or longer treatment duration, terbinafine maintains better tolerability, as fluconazole's discontinuation rate escalates dramatically with dose intensification, according to the British Journal of Dermatology 7